Identification

Name
Ibandronate
Accession Number
DB00710  (APRD00231, DB04635)
Type
Small Molecule
Groups
Approved, Investigational
Description

Ibandronate is a nitrogen-containing bisphosphonate in the same class as alendronate and risedronate. Ibandronate inhibits osteoclast-mediated bone resorption. All of the bisphosphonates prevent the breakdown of bone by bone cells called osteoclasts. In persons who are at high risk for osteoporosis, bisphosphonates not only result in increased amounts of bone and bone strength, they also reduce the risk of hip fractures and other bone fractures.

Structure
Thumb
Synonyms
  • Ibandronic Acid
External IDs
R484
Product Ingredients
IngredientUNIICASInChI Key
Ibandronate sodium23Y0B94E49138926-19-9LXLBEOAZMZAZND-UHFFFAOYSA-M
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
BondronatLiquid1 mgIntravenousHoffmann La Roche2004-05-312006-05-17Canada
BonivaTablet, film coated150 mg/1OralPhysicians Total Care, Inc.2005-06-02Not applicableUs
BonivaTablet, film coated150 mg/1OralGenentech, Inc.2002-07-15Not applicableUs
BonivaInjection, solution3 mg/3mLIntravenousGenentech, Inc.2011-06-01Not applicableUs
BonvivaTablet, film coated150 mgOralRoche Registration Limited2004-02-23Not applicableEu
BonvivaInjection, solution3 mgIntravenousRoche Registration Limited2004-02-23Not applicableEu
BonvivaTablet, film coated150 mgOralRoche Registration Limited2004-02-23Not applicableEu
BonvivaInjection, solution3 mgIntravenousRoche Registration Limited2004-02-23Not applicableEu
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
IasibonTablet, film coated50 mgOralPharmathen S.A.2011-01-21Not applicableEu
IasibonInjection, solution, concentrate6 mgIntravenousPharmathen S.A.2011-01-21Not applicableEu
IasibonTablet, film coated50 mgOralPharmathen S.A.2011-01-21Not applicableEu
IasibonInjection, solution, concentrate1 mgIntravenousPharmathen S.A.2011-01-21Not applicableEu
IasibonInjection, solution, concentrate6 mgIntravenousPharmathen S.A.2011-01-21Not applicableEu
IasibonTablet, film coated50 mgOralPharmathen S.A.2011-01-21Not applicableEu
IasibonTablet, film coated50 mgOralPharmathen S.A.2011-01-21Not applicableEu
IasibonInjection, solution, concentrate2 mgIntravenousPharmathen S.A.2011-01-21Not applicableEu
IasibonInjection, solution, concentrate6 mgIntravenousPharmathen S.A.2011-01-21Not applicableEu
IasibonTablet, film coated50 mgOralPharmathen S.A.2011-01-21Not applicableEu
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
BondenzaTablet, film coated150 mgOralRoche Registration Limited2004-02-23Not applicableEu
BondenzaInjection, solution3 mgIntravenousRoche Registration Limited2004-02-23Not applicableEu
BondenzaTablet, film coated150 mgOralRoche Registration Limited2004-02-23Not applicableEu
BondenzaInjection, solution3 mgIntravenousRoche Registration Limited2004-02-23Not applicableEu
Ibandronate SodiumTablet, film coated150 mg/1OralMacleods Pharmaceuticals Limited2017-11-01Not applicableUs
International/Other Brands
ADRONiL / Bondronat / Bonviva
Categories
UNII
UMD7G2653W
CAS number
114084-78-5
Weight
Average: 319.2289
Monoisotopic: 319.094975119
Chemical Formula
C9H23NO7P2
InChI Key
MPBVHIBUJCELCL-UHFFFAOYSA-N
InChI
InChI=1S/C9H23NO7P2/c1-3-4-5-7-10(2)8-6-9(11,18(12,13)14)19(15,16)17/h11H,3-8H2,1-2H3,(H2,12,13,14)(H2,15,16,17)
IUPAC Name
{1-hydroxy-3-[methyl(pentyl)amino]-1-phosphonopropyl}phosphonic acid
SMILES
CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O

Pharmacology

Indication

For the treatment and prevention of osteoporosis in postmenopausal women.

Structured Indications
Pharmacodynamics

Ibandronate is a nitrogen-containing bisphosphonate in the same class as alendronate and risedronate. Ibandronate inhibits osteoclast-mediated bone resorption. All of the bisphosphonates prevent the breakdown of bone by bone cells called osteoclasts. In persons who are at high risk for osteoporosis, bisphosphonates not only result in increased amounts of bone and bone strength, they also reduce the risk of hip fractures and other bone fractures.

Mechanism of action

The action of ibandronate on bone tissue is based partly on its affinity for hydroxyapatite, which is part of the mineral matrix of bone. Nitrogen-containing bisphosphonates (such as pamidronate, alendronate, risedronate, ibandronate and zoledronate) appear to act as analogues of isoprenoid diphosphate lipids, thereby inhibiting farnesyl pyrophosphate (FPP) synthase, an enzyme in the mevalonate pathway. Inhibition of this enzyme in osteoclasts prevents the biosynthesis of isoprenoid lipids (FPP and GGPP) that are essential for the post-translational farnesylation and geranylgeranylation of small GTPase signalling proteins. This activity inhibits osteoclast activity and reduces bone resorption and turnover. In postmenopausal women, it reduces the elevated rate of bone turnover, leading to, on average, a net gain in bone mass.

TargetActionsOrganism
AFarnesyl pyrophosphate synthase
inhibitor
Human
AHydroxylapatite
antagonist
Human
Absorption

Poorly absorbed (mean bioavailability following a 2.5 mg oral dose is about 0.6% compared to intravenous dosing). Absorption is impaired by any kind of food or drink other than plain water.

Volume of distribution
  • 90 L
Protein binding

90.9 to 99.5% over an ibandronate concentration range of 2 to 10 ng/mL

Metabolism

No evidence of ibandronate being metabolized in humans.

Route of elimination

Ibandronate is eliminated by renal excretion. Unabsorbed ibandronate is eliminated unchanged in the feces.

Half life

10-60 hours

Clearance
  • 84 to 160 mL/min [IV administration]
Toxicity

LD50 = 811 mg/kg (rat, oral), side effects include bronchitis, pneumonia and urinary tract infections.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Ibandronate Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Ibandronate.Approved, Investigational
AcemetacinThe risk or severity of adverse effects can be increased when Acemetacin is combined with Ibandronate.Approved
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Ibandronate.Approved, Vet Approved
AclarubicinAclarubicin may increase the hypocalcemic activities of Ibandronate.Investigational
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Ibandronate.Approved
AlclofenacThe risk or severity of adverse effects can be increased when Alclofenac is combined with Ibandronate.Approved, Withdrawn
AlgeldrateThe serum concentration of Ibandronate can be decreased when it is combined with Algeldrate.Approved, Experimental
AlmagateThe serum concentration of Ibandronate can be decreased when it is combined with Almagate.Experimental
AlmasilateThe serum concentration of Ibandronate can be decreased when it is combined with Almasilate.Approved, Experimental
AlminoprofenThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Ibandronate.Experimental
AloglutamolThe serum concentration of Ibandronate can be decreased when it is combined with Aloglutamol.Experimental
AluminiumThe serum concentration of Ibandronate can be decreased when it is combined with Aluminium.Approved
Aluminium acetoacetateThe serum concentration of Ibandronate can be decreased when it is combined with Aluminium acetoacetate.Experimental
Aluminium glycinateThe serum concentration of Ibandronate can be decreased when it is combined with Aluminium glycinate.Experimental
Aluminum hydroxideThe serum concentration of Ibandronate can be decreased when it is combined with Aluminum hydroxide.Approved
AmikacinAmikacin may increase the hypocalcemic activities of Ibandronate.Approved, Vet Approved
AmiodaroneIbandronate may increase the QTc-prolonging activities of Amiodarone.Approved, Investigational
AmrubicinAmrubicin may increase the hypocalcemic activities of Ibandronate.Approved, Investigational
AnagrelideIbandronate may increase the QTc-prolonging activities of Anagrelide.Approved
AndrographolideThe risk or severity of adverse effects can be increased when Andrographolide is combined with Ibandronate.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Anisodamine is combined with Ibandronate.Investigational
annamycinannamycin may increase the hypocalcemic activities of Ibandronate.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Ibandronate.Approved
ApocyninThe risk or severity of adverse effects can be increased when Apocynin is combined with Ibandronate.Investigational
ApramycinApramycin may increase the hypocalcemic activities of Ibandronate.Experimental, Vet Approved
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Ibandronate.Approved, Investigational
ArbekacinArbekacin may increase the hypocalcemic activities of Ibandronate.Approved, Investigational
Arsenic trioxideIbandronate may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
ArtemetherIbandronate may increase the QTc-prolonging activities of Artemether.Approved
AsenapineIbandronate may increase the QTc-prolonging activities of Asenapine.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Ibandronate.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Ibandronate.Approved
AzithromycinIbandronate may increase the QTc-prolonging activities of Azithromycin.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Ibandronate.Approved, Investigational
BedaquilineIbandronate may increase the QTc-prolonging activities of Bedaquiline.Approved
BekanamycinBekanamycin may increase the hypocalcemic activities of Ibandronate.Experimental
BendazacThe risk or severity of adverse effects can be increased when Bendazac is combined with Ibandronate.Experimental
BenorilateThe risk or severity of adverse effects can be increased when Benorilate is combined with Ibandronate.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Ibandronate.Withdrawn
BevoniumThe risk or severity of adverse effects can be increased when Bevonium is combined with Ibandronate.Experimental
Bismuth SubcitrateThe serum concentration of Ibandronate can be decreased when it is combined with Bismuth Subcitrate.Approved
Bismuth subnitrateThe serum concentration of Ibandronate can be decreased when it is combined with Bismuth subnitrate.Experimental
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Ibandronate.Approved
BucillamineThe risk or severity of adverse effects can be increased when Bucillamine is combined with Ibandronate.Investigational
BufexamacThe risk or severity of adverse effects can be increased when Bufexamac is combined with Ibandronate.Experimental
BumadizoneThe risk or severity of adverse effects can be increased when Bumadizone is combined with Ibandronate.Experimental
CalciumThe serum concentration of Ibandronate can be decreased when it is combined with Calcium.Approved, Nutraceutical
Calcium AcetateThe serum concentration of Ibandronate can be decreased when it is combined with Calcium Acetate.Approved
Calcium CarbonateThe serum concentration of Ibandronate can be decreased when it is combined with Calcium Carbonate.Approved
Calcium CitrateThe serum concentration of Ibandronate can be decreased when it is combined with Calcium Citrate.Approved
Calcium glubionateThe serum concentration of Ibandronate can be decreased when it is combined with Calcium glubionate.Approved
Calcium GluceptateThe serum concentration of Ibandronate can be decreased when it is combined with Calcium Gluceptate.Approved
Calcium gluconateThe serum concentration of Ibandronate can be decreased when it is combined with Calcium gluconate.Approved, Vet Approved
Calcium lactateThe serum concentration of Ibandronate can be decreased when it is combined with Calcium lactate.Approved, Experimental, Investigational, Vet Approved
Calcium lactate gluconateThe serum concentration of Ibandronate can be decreased when it is combined with Calcium lactate gluconate.Experimental
Calcium laevulateThe serum concentration of Ibandronate can be decreased when it is combined with Calcium laevulate.Experimental
Calcium pangamateThe serum concentration of Ibandronate can be decreased when it is combined with Calcium pangamate.Experimental
Calcium PhosphateThe serum concentration of Ibandronate can be decreased when it is combined with Calcium Phosphate.Approved
Calcium silicateThe serum concentration of Ibandronate can be decreased when it is combined with Calcium silicate.Experimental
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Ibandronate.Experimental, Investigational
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Ibandronate.Approved, Vet Approved, Withdrawn
CaseinThe serum concentration of Ibandronate can be decreased when it is combined with Casein.Approved
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Ibandronate.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Ibandronate.Approved, Investigational
CeritinibIbandronate may increase the QTc-prolonging activities of Ceritinib.Approved
ChloroquineIbandronate may increase the QTc-prolonging activities of Chloroquine.Approved, Vet Approved
ChlorpromazineIbandronate may increase the QTc-prolonging activities of Chlorpromazine.Approved, Vet Approved
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Ibandronate.Approved
CiprofloxacinIbandronate may increase the QTc-prolonging activities of Ciprofloxacin.Approved, Investigational
CisaprideIbandronate may increase the QTc-prolonging activities of Cisapride.Approved, Investigational, Withdrawn
CitalopramIbandronate may increase the QTc-prolonging activities of Citalopram.Approved
ClarithromycinIbandronate may increase the QTc-prolonging activities of Clarithromycin.Approved
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with Ibandronate.Approved
ClozapineIbandronate may increase the QTc-prolonging activities of Clozapine.Approved
CrizotinibIbandronate may increase the QTc-prolonging activities of Crizotinib.Approved
CurcuminThe risk or severity of adverse effects can be increased when Curcumin is combined with Ibandronate.Investigational
D-LimoneneThe risk or severity of adverse effects can be increased when D-Limonene is combined with Ibandronate.Investigational
DaunorubicinDaunorubicin may increase the hypocalcemic activities of Ibandronate.Approved
DeferasiroxThe risk or severity of adverse effects can be increased when Ibandronate is combined with Deferasirox.Approved, Investigational
DexlansoprazoleThe therapeutic efficacy of Ibandronate can be decreased when used in combination with Dexlansoprazole.Approved
DexrabeprazoleThe therapeutic efficacy of Ibandronate can be decreased when used in combination with Dexrabeprazole.Experimental
DibekacinDibekacin may increase the hypocalcemic activities of Ibandronate.Experimental
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Ibandronate.Approved, Vet Approved
DifenpiramideThe risk or severity of adverse effects can be increased when Difenpiramide is combined with Ibandronate.Experimental
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Ibandronate.Approved
DihydrostreptomycinDihydrostreptomycin may increase the hypocalcemic activities of Ibandronate.Investigational, Vet Approved
DisopyramideIbandronate may increase the QTc-prolonging activities of Disopyramide.Approved
DofetilideIbandronate may increase the QTc-prolonging activities of Dofetilide.Approved
DolasetronIbandronate may increase the QTc-prolonging activities of Dolasetron.Approved
DomperidoneIbandronate may increase the QTc-prolonging activities of Domperidone.Approved, Investigational, Vet Approved
DoxorubicinDoxorubicin may increase the hypocalcemic activities of Ibandronate.Approved, Investigational
DronedaroneIbandronate may increase the QTc-prolonging activities of Dronedarone.Approved
DroperidolIbandronate may increase the QTc-prolonging activities of Droperidol.Approved, Vet Approved
DroxicamThe risk or severity of adverse effects can be increased when Droxicam is combined with Ibandronate.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Duvelisib is combined with Ibandronate.Investigational
E-6201The risk or severity of adverse effects can be increased when E-6201 is combined with Ibandronate.Investigational
EliglustatIbandronate may increase the QTc-prolonging activities of Eliglustat.Approved
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Ibandronate.Approved
EpirubicinEpirubicin may increase the hypocalcemic activities of Ibandronate.Approved
ErythromycinIbandronate may increase the QTc-prolonging activities of Erythromycin.Approved, Vet Approved
EscitalopramIbandronate may increase the QTc-prolonging activities of Escitalopram.Approved, Investigational
EsomeprazoleThe therapeutic efficacy of Ibandronate can be decreased when used in combination with Esomeprazole.Approved, Investigational
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Ibandronate.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Ethenzamide is combined with Ibandronate.Experimental
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Ibandronate.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Ibandronate.Approved, Investigational
EtoricoxibThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Ibandronate.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Evening primrose oil is combined with Ibandronate.Approved, Investigational
exisulindThe risk or severity of adverse effects can be increased when exisulind is combined with Ibandronate.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Felbinac is combined with Ibandronate.Experimental
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Ibandronate.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Ibandronate.Approved
FentiazacThe risk or severity of adverse effects can be increased when Fentiazac is combined with Ibandronate.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Feprazone is combined with Ibandronate.Experimental
Ferric CitrateThe serum concentration of Ibandronate can be decreased when it is combined with Ferric Citrate.Approved, Investigational
Ferulic acidThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Ibandronate.Experimental
FlecainideIbandronate may increase the QTc-prolonging activities of Flecainide.Approved, Withdrawn
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Ibandronate.Approved, Withdrawn
FlunixinThe risk or severity of adverse effects can be increased when Flunixin is combined with Ibandronate.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Flunoxaprofen is combined with Ibandronate.Experimental
FluoxetineIbandronate may increase the QTc-prolonging activities of Fluoxetine.Approved, Vet Approved
FlupentixolIbandronate may increase the QTc-prolonging activities of Flupentixol.Approved, Withdrawn
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Ibandronate.Approved, Investigational
FramycetinFramycetin may increase the hypocalcemic activities of Ibandronate.Approved
Gadobenic acidIbandronate may increase the QTc-prolonging activities of Gadobenic acid.Approved
GemifloxacinIbandronate may increase the QTc-prolonging activities of Gemifloxacin.Approved, Investigational
GeneticinGeneticin may increase the hypocalcemic activities of Ibandronate.Experimental
GentamicinGentamicin may increase the hypocalcemic activities of Ibandronate.Approved, Vet Approved
GENTAMICIN C1AGENTAMICIN C1A may increase the hypocalcemic activities of Ibandronate.Experimental
GoserelinIbandronate may increase the QTc-prolonging activities of Goserelin.Approved
GPX-150GPX-150 may increase the hypocalcemic activities of Ibandronate.Investigational
GranisetronIbandronate may increase the QTc-prolonging activities of Granisetron.Approved, Investigational
GuacetisalThe risk or severity of adverse effects can be increased when Guacetisal is combined with Ibandronate.Experimental
HaloperidolIbandronate may increase the QTc-prolonging activities of Haloperidol.Approved
HigenamineThe risk or severity of adverse effects can be increased when Higenamine is combined with Ibandronate.Investigational
HydrotalciteThe serum concentration of Ibandronate can be decreased when it is combined with Hydrotalcite.Experimental, Investigational
Hygromycin BHygromycin B may increase the hypocalcemic activities of Ibandronate.Vet Approved
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Ibandronate.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Ibandronate.Withdrawn
IbutilideIbandronate may increase the QTc-prolonging activities of Ibutilide.Approved
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Ibandronate.Approved
IdarubicinIdarubicin may increase the hypocalcemic activities of Ibandronate.Approved
IloperidoneIbandronate may increase the QTc-prolonging activities of Iloperidone.Approved
Imidazole salicylateThe risk or severity of adverse effects can be increased when Imidazole salicylate is combined with Ibandronate.Experimental
IndobufenThe risk or severity of adverse effects can be increased when Indobufen is combined with Ibandronate.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Ibandronate.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Ibandronate.Withdrawn
INNO-206INNO-206 may increase the hypocalcemic activities of Ibandronate.Investigational
Iron saccharateThe serum concentration of Ibandronate can be decreased when it is combined with Iron saccharate.Approved
IsepamicinIsepamicin may increase the hypocalcemic activities of Ibandronate.Experimental
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Ibandronate.Withdrawn
KanamycinKanamycin may increase the hypocalcemic activities of Ibandronate.Approved, Investigational, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Ibandronate.Experimental
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Ibandronate.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Ibandronate.Approved
LansoprazoleThe therapeutic efficacy of Ibandronate can be decreased when used in combination with Lansoprazole.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Ibandronate.Approved, Investigational
LenvatinibIbandronate may increase the QTc-prolonging activities of Lenvatinib.Approved
LeuprolideIbandronate may increase the QTc-prolonging activities of Leuprolide.Approved, Investigational
LevofloxacinIbandronate may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Ibandronate.Investigational
LonazolacThe risk or severity of adverse effects can be increased when Lonazolac is combined with Ibandronate.Experimental
LopinavirIbandronate may increase the QTc-prolonging activities of Lopinavir.Approved
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Ibandronate.Approved, Investigational
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Ibandronate.Approved, Investigational
LumefantrineIbandronate may increase the QTc-prolonging activities of Lumefantrine.Approved
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Ibandronate.Approved, Investigational
Magnesium HydroxideThe serum concentration of Ibandronate can be decreased when it is combined with Magnesium Hydroxide.Approved
Magnesium oxideThe serum concentration of Ibandronate can be decreased when it is combined with Magnesium oxide.Approved
Magnesium peroxideThe serum concentration of Ibandronate can be decreased when it is combined with Magnesium peroxide.Experimental
Magnesium salicylateThe serum concentration of Ibandronate can be decreased when it is combined with Magnesium salicylate.Approved
Magnesium silicateThe serum concentration of Ibandronate can be decreased when it is combined with Magnesium silicate.Approved, Experimental
Magnesium SulfateThe serum concentration of Ibandronate can be decreased when it is combined with Magnesium Sulfate.Approved, Vet Approved
Magnesium TrisilicateThe serum concentration of Ibandronate can be decreased when it is combined with Magnesium Trisilicate.Approved
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Ibandronate.Approved, Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Ibandronate.Approved, Vet Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Ibandronate.Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Ibandronate.Approved, Vet Approved
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Ibandronate.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Ibandronate.Investigational, Withdrawn
MethadoneIbandronate may increase the QTc-prolonging activities of Methadone.Approved
MetrizamideMetrizamide may increase the hypocalcemic activities of Ibandronate.Approved
MicronomicinMicronomicin may increase the hypocalcemic activities of Ibandronate.Experimental
MifepristoneMifepristone may increase the QTc-prolonging activities of Ibandronate.Approved, Investigational
MizoribineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Ibandronate.Investigational
MofebutazoneThe risk or severity of adverse effects can be increased when Mofebutazone is combined with Ibandronate.Experimental
MoxifloxacinIbandronate may increase the QTc-prolonging activities of Moxifloxacin.Approved, Investigational
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Ibandronate.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Ibandronate.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Ibandronate.Approved
NafamostatThe risk or severity of adverse effects can be increased when Nafamostat is combined with Ibandronate.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Ibandronate.Approved
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Ibandronate.Approved, Vet Approved
NeamineNeamine may increase the hypocalcemic activities of Ibandronate.Experimental
NeomycinNeomycin may increase the hypocalcemic activities of Ibandronate.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Ibandronate.Approved
NetilmicinNetilmicin may increase the hypocalcemic activities of Ibandronate.Approved, Investigational
NifenazoneThe risk or severity of adverse effects can be increased when Nifenazone is combined with Ibandronate.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Ibandronate.Approved
NilotinibIbandronate may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Ibandronate.Approved, Investigational, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Ibandronate.Investigational
OfloxacinIbandronate may increase the QTc-prolonging activities of Ofloxacin.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Ibandronate.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Ibandronate.Approved
OmeprazoleThe therapeutic efficacy of Ibandronate can be decreased when used in combination with Omeprazole.Approved, Investigational, Vet Approved
OndansetronIbandronate may increase the QTc-prolonging activities of Ondansetron.Approved
OrgoteinThe risk or severity of adverse effects can be increased when Orgotein is combined with Ibandronate.Vet Approved
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Ibandronate.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Ibandronate.Approved, Withdrawn
PaliperidoneIbandronate may increase the QTc-prolonging activities of Paliperidone.Approved
PanobinostatIbandronate may increase the QTc-prolonging activities of Panobinostat.Approved, Investigational
PantoprazoleThe therapeutic efficacy of Ibandronate can be decreased when used in combination with Pantoprazole.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Parecoxib is combined with Ibandronate.Approved
ParomomycinParomomycin may increase the hypocalcemic activities of Ibandronate.Approved, Investigational
ParthenolideThe risk or severity of adverse effects can be increased when Parthenolide is combined with Ibandronate.Investigational
PazopanibIbandronate may increase the QTc-prolonging activities of Pazopanib.Approved
PentamidineIbandronate may increase the QTc-prolonging activities of Pentamidine.Approved
PerflutrenIbandronate may increase the QTc-prolonging activities of Perflutren.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Ibandronate.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Ibandronate.Approved, Investigational
PimozideIbandronate may increase the QTc-prolonging activities of Pimozide.Approved
PirarubicinPirarubicin may increase the hypocalcemic activities of Ibandronate.Investigational
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Ibandronate.Approved, Investigational
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Ibandronate.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Pirprofen is combined with Ibandronate.Experimental
PlazomicinPlazomicin may increase the hypocalcemic activities of Ibandronate.Investigational
PlicamycinPlicamycin may increase the hypocalcemic activities of Ibandronate.Approved, Investigational, Withdrawn
PranoprofenThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Ibandronate.Experimental, Investigational
PrimaquineIbandronate may increase the QTc-prolonging activities of Primaquine.Approved
ProcainamideIbandronate may increase the QTc-prolonging activities of Procainamide.Approved
ProglumetacinThe risk or severity of adverse effects can be increased when Proglumetacin is combined with Ibandronate.Experimental
PromazineIbandronate may increase the QTc-prolonging activities of Promazine.Approved, Vet Approved
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Ibandronate.Approved, Investigational
PropafenoneIbandronate may increase the QTc-prolonging activities of Propafenone.Approved
PropyphenazoneThe risk or severity of adverse effects can be increased when Propyphenazone is combined with Ibandronate.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Proquazone is combined with Ibandronate.Experimental
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Ibandronate.Investigational
PuromycinPuromycin may increase the hypocalcemic activities of Ibandronate.Experimental
QuetiapineIbandronate may increase the QTc-prolonging activities of Quetiapine.Approved
QuinidineIbandronate may increase the QTc-prolonging activities of Quinidine.Approved
QuinineIbandronate may increase the QTc-prolonging activities of Quinine.Approved
RabeprazoleThe therapeutic efficacy of Ibandronate can be decreased when used in combination with Rabeprazole.Approved, Investigational
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Ibandronate.Approved, Experimental, Investigational
RibostamycinRibostamycin may increase the hypocalcemic activities of Ibandronate.Approved, Investigational
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Ibandronate.Investigational, Withdrawn
SabarubicinSabarubicin may increase the hypocalcemic activities of Ibandronate.Investigational
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Ibandronate.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Ibandronate.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Ibandronate.Approved
SaquinavirIbandronate may increase the QTc-prolonging activities of Saquinavir.Approved, Investigational
SemapimodThe risk or severity of adverse effects can be increased when Semapimod is combined with Ibandronate.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Ibandronate.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Ibandronate.Investigational
SisomicinSisomicin may increase the hypocalcemic activities of Ibandronate.Investigational
SotalolIbandronate may increase the QTc-prolonging activities of Sotalol.Approved
SP1049CSP1049C may increase the hypocalcemic activities of Ibandronate.Investigational
SpectinomycinSpectinomycin may increase the hypocalcemic activities of Ibandronate.Approved, Investigational, Vet Approved
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Ibandronate.Investigational
StreptomycinStreptomycin may increase the hypocalcemic activities of Ibandronate.Approved, Vet Approved
StreptozocinStreptozocin may increase the hypocalcemic activities of Ibandronate.Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Ibandronate.Approved
SulfisoxazoleIbandronate may increase the QTc-prolonging activities of Sulfisoxazole.Approved, Vet Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Ibandronate.Approved
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Ibandronate.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Suxibuzone is combined with Ibandronate.Experimental
TarenflurbilThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Ibandronate.Investigational
TelavancinIbandronate may increase the QTc-prolonging activities of Telavancin.Approved
TelithromycinIbandronate may increase the QTc-prolonging activities of Telithromycin.Approved
TenidapThe risk or severity of adverse effects can be increased when Tenidap is combined with Ibandronate.Experimental
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Ibandronate.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with Ibandronate.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Ibandronate.Approved
TetrabenazineIbandronate may increase the QTc-prolonging activities of Tetrabenazine.Approved
ThioridazineIbandronate may increase the QTc-prolonging activities of Thioridazine.Approved, Withdrawn
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Ibandronate.Approved
TinoridineThe risk or severity of adverse effects can be increased when Tinoridine is combined with Ibandronate.Investigational
TobramycinTobramycin may increase the hypocalcemic activities of Ibandronate.Approved, Investigational
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Ibandronate.Approved
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Ibandronate.Approved
ToremifeneIbandronate may increase the QTc-prolonging activities of Toremifene.Approved, Investigational
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Ibandronate.Approved, Investigational
TribenosideThe risk or severity of adverse effects can be increased when Tribenoside is combined with Ibandronate.Experimental
TriptolideThe risk or severity of adverse effects can be increased when Triptolide is combined with Ibandronate.Investigational
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Ibandronate.Investigational, Withdrawn
ValrubicinValrubicin may increase the hypocalcemic activities of Ibandronate.Approved
VandetanibIbandronate may increase the QTc-prolonging activities of Vandetanib.Approved
VemurafenibIbandronate may increase the QTc-prolonging activities of Vemurafenib.Approved
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Ibandronate.Approved, Investigational
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Ibandronate.Approved, Investigational, Withdrawn
ZiprasidoneIbandronate may increase the QTc-prolonging activities of Ziprasidone.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Ibandronate.Withdrawn
Zoptarelin doxorubicinZoptarelin doxorubicin may increase the hypocalcemic activities of Ibandronate.Investigational
ZorubicinZorubicin may increase the hypocalcemic activities of Ibandronate.Experimental
ZuclopenthixolIbandronate may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational
Food Interactions
  • Take on an empty stomach. All foods markedly reduce (up to 90%) ibandronate bioavailabilty. Take with plain water (not mineralized) at least 1 hour before any food. Bioavailability and effect on bone density are both impaired if the patient eats or drinks in less than 1 hour after taking this product. Drink a large glass of water and stay in an upright position for at least 60 minutes after taking this product.

References

Synthesis Reference

Revital Lifshitz-Liron, Thomas Bayer, Judith Aronhime, Michael Pinchasov, "Solid and crystalline ibandronate sodium and processes for preparation thereof." U.S. Patent US20070179119, issued August 02, 2007.

US20070179119
General References
  1. Epstein S, Zaidi M: Biological properties and mechanism of action of ibandronate: application to the treatment of osteoporosis. Bone. 2005 Oct;37(4):433-40. [PubMed:16046205]
External Links
Human Metabolome Database
HMDB14848
PubChem Compound
60852
PubChem Substance
46508134
ChemSpider
54839
BindingDB
12577
ChEMBL
CHEMBL997
Therapeutic Targets Database
DAP001022
PharmGKB
PA10270
HET
BFQ
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Ibandronate
ATC Codes
M05BA06 — Ibandronic acid
PDB Entries
2f94 / 4umj
FDA label
Download (296 KB)
MSDS
Download (16 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedNot AvailableHealthy Volunteers1
1CompletedTreatmentHealthy Volunteers1
2CompletedTreatmentCancer, Breast1
2CompletedTreatmentPain; Bone Neoplasms; Neoplasm Metastasis1
2RecruitingTreatmentBone destruction1
2Unknown StatusTreatmentCancer, Breast1
2Unknown StatusTreatmentOsteoporosis, Post-Menopausal1
2WithdrawnTreatmentBone Neoplasms / Neoplasms Metastasis / Pain1
2, 3CompletedTreatmentBone destruction1
2, 3Unknown StatusTreatmentTransplant, Kidney1
3Active Not RecruitingTreatmentCancer, Breast1
3CompletedSupportive CareMetastatic Cancers / Pain / Prostate Cancer1
3CompletedTreatmentBone Marrow Edema of the Knee / Osteonecrosis of the Knee1
3CompletedTreatmentCancer, Breast1
3CompletedTreatmentHaematological Malignancies1
3CompletedTreatmentMale Osteoporosis1
3CompletedTreatmentOsteoporosis, Post-Menopausal1
3CompletedTreatmentPain; Bone Neoplasms; Neoplasm Metastasis2
3CompletedTreatmentPost Menopausal Osteoporosis3
3CompletedTreatmentPost-Menopausal Osteopenia1
3CompletedTreatmentPostmenopausal Osteoporosis (PMO)2
3CompletedTreatmentPostmenopausal Women With Osteoporosis1
3CompletedTreatmentPrimary Osteoporosis1
3CompletedTreatmentBone destruction1
3TerminatedTreatmentAseptic / Aseptic Hip Necrosis / Hip Necrosis1
3TerminatedTreatmentBone Neoplasms / Neoplasms Metastasis / Pain2
3TerminatedTreatmentMultiple Myeloma (MM)1
3Unknown StatusTreatmentCancer, Breast / Hypercalcemia of Malignancy / Metastatic Cancers1
3WithdrawnSupportive CareCancer, Breast / Hypercalcemia of Malignancy / Metastatic Cancers / Pain1
4CompletedPreventionBone destruction / Osteopenia / Rheumatoid Arthritis1
4CompletedTreatmentOsteoporosis, Post-Menopausal3
4CompletedTreatmentPain; Bone Neoplasms; Neoplasm Metastasis2
4CompletedTreatmentPost Menopausal Osteoporosis5
4CompletedTreatmentPost-Menopausal Osteopenia1
4CompletedTreatmentPostmenopausal Osteoporosis (PMO)8
4CompletedTreatmentSystemic Lupus Erythematosus (SLE)1
4CompletedTreatmentBone destruction3
4No Longer AvailableNot AvailablePostmenopausal Osteoporosis (PMO)1
4SuspendedTreatmentHuman Immunodeficiency Virus (HIV) Infections1
4TerminatedTreatmentLung Cancers1
4TerminatedTreatmentBone destruction1
Not AvailableCompletedNot AvailableAdenocarcinomas / Esophageal Cancers / Squamous Cell Carcinoma (SCC)1
Not AvailableCompletedNot AvailablePostmenopausal Osteoporosis (PMO)1
Not AvailableCompletedNot AvailableBone destruction3
Not AvailableEnrolling by InvitationNot AvailableAtypical Femoral Fractures / Bisphosphonate Therapy / Bone destruction1
Not AvailableWithdrawnNot AvailableCancer, Breast1

Pharmacoeconomics

Manufacturers
  • Hoffmann la roche inc
Packagers
Dosage forms
FormRouteStrength
Injection, solutionIntravenous3 mg
Tablet, film coatedOral150 mg
LiquidIntravenous1 mg
Tablet, film coatedOral150 mg/1
Injection, solution, concentrateIntravenous1 mg
Injection, solution, concentrateIntravenous2 mg
Injection, solution, concentrateIntravenous6 mg
Tablet, film coatedOral50 mg
InjectionIntravenous3 mg/3mL
Injection, solutionIntravenous3 mg/3mL
TabletOral150 mg/1
Prices
Unit descriptionCostUnit
Boniva 3 mg/3ml Kit Box524.22USD box
Boniva 3 mg/3 ml syringe504.06USD syringe
Boniva 3 150 mg tablet Disp Pack388.93USD disp
Boniva 150 mg tablet124.66USD tablet
Boniva 2.5 mg tablet4.16USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US4927814No1995-03-172012-03-17Us
CA2346662No2006-05-092019-10-01Canada
US7192938Yes2003-11-062023-11-06Us
US7718634Yes2003-11-062023-11-06Us
US7410957No2003-05-062023-05-06Us
US6294196No1999-10-072019-10-07Us
US6143326No1997-04-212017-04-21Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
water solubilityFreely solubleNot Available
logP-2.1Not Available
Predicted Properties
PropertyValueSource
Water Solubility13.4 mg/mLALOGPS
logP0.26ALOGPS
logP-2.5ChemAxon
logS-1.4ALOGPS
pKa (Strongest Acidic)0.66ChemAxon
pKa (Strongest Basic)9.93ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count8ChemAxon
Hydrogen Donor Count5ChemAxon
Polar Surface Area138.53 Å2ChemAxon
Rotatable Bond Count9ChemAxon
Refractivity71.16 m3·mol-1ChemAxon
Polarizability29.51 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.9664
Blood Brain Barrier-0.5229
Caco-2 permeable-0.6012
P-glycoprotein substrateSubstrate0.6888
P-glycoprotein inhibitor INon-inhibitor0.8195
P-glycoprotein inhibitor IINon-inhibitor0.9838
Renal organic cation transporterNon-inhibitor0.9092
CYP450 2C9 substrateNon-substrate0.8376
CYP450 2D6 substrateNon-substrate0.7863
CYP450 3A4 substrateNon-substrate0.5504
CYP450 1A2 substrateNon-inhibitor0.832
CYP450 2C9 inhibitorNon-inhibitor0.8159
CYP450 2D6 inhibitorNon-inhibitor0.8987
CYP450 2C19 inhibitorNon-inhibitor0.8045
CYP450 3A4 inhibitorNon-inhibitor0.8901
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9945
Ames testNon AMES toxic0.6527
CarcinogenicityNon-carcinogens0.683
BiodegradationNot ready biodegradable0.8346
Rat acute toxicity2.4278 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.6061
hERG inhibition (predictor II)Non-inhibitor0.6622
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as bisphosphonates. These are organic compounds containing two phosphonate groups linked together through a carbon atoms.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Organic phosphonic acids and derivatives
Sub Class
Bisphosphonates
Direct Parent
Bisphosphonates
Alternative Parents
Organic phosphonic acids / 1,3-aminoalcohols / Trialkylamines / Organopnictogen compounds / Organophosphorus compounds / Organooxygen compounds / Organic oxides / Hydrocarbon derivatives
Substituents
Bisphosphonate / Organophosphonic acid / 1,3-aminoalcohol / Tertiary aliphatic amine / Tertiary amine / Organic nitrogen compound / Organic oxygen compound / Organopnictogen compound / Organic oxide / Hydrocarbon derivative
Molecular Framework
Aliphatic acyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Poly(a) rna binding
Specific Function
Key enzyme in isoprenoid biosynthesis which catalyzes the formation of farnesyl diphosphate (FPP), a precursor for several classes of essential metabolites including sterols, dolichols, carotenoids...
Gene Name
FDPS
Uniprot ID
P14324
Uniprot Name
Farnesyl pyrophosphate synthase
Molecular Weight
48275.03 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Chapurlat RD, Delmas PD: Drug insight: Bisphosphonates for postmenopausal osteoporosis. Nat Clin Pract Endocrinol Metab. 2006 Apr;2(4):211-9; quiz following 238. [PubMed:16932286]
  3. Dunford JE, Thompson K, Coxon FP, Luckman SP, Hahn FM, Poulter CD, Ebetino FH, Rogers MJ: Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther. 2001 Feb;296(2):235-42. [PubMed:11160603]
  4. Rondeau JM, Bitsch F, Bourgier E, Geiser M, Hemmig R, Kroemer M, Lehmann S, Ramage P, Rieffel S, Strauss A, Green JR, Jahnke W: Structural basis for the exceptional in vivo efficacy of bisphosphonate drugs. ChemMedChem. 2006 Feb;1(2):267-73. [PubMed:16892359]
Kind
Small molecule
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
References
  1. Jahnke W, Henry C: An in vitro assay to measure targeted drug delivery to bone mineral. ChemMedChem. 2010 May 3;5(5):770-6. doi: 10.1002/cmdc.201000016. [PubMed:20209564]
  2. Nancollas GH, Tang R, Phipps RJ, Henneman Z, Gulde S, Wu W, Mangood A, Russell RG, Ebetino FH: Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone. 2006 May;38(5):617-27. Epub 2005 Jul 20. [PubMed:16046206]

Drug created on June 13, 2005 07:24 / Updated on November 07, 2017 01:41